Key result
Modulating dual antiplatelet therapy duration and intensity based on patient-specific risk profiles may optimize ischemic and bleeding outcomes in acute coronary syndrome.
Why the study?
While DAPT is the current standard, it increases bleeding risk, necessitating modulation of its duration and intensity according to individual patient risk profiles.
Answers are grounded in this paper and cite their sources.
Personalized antiplatelet strategies, guided by clinical characteristics and potentially genetic/platelet function testing, are recommended to balance ischemic and bleeding risks in ACS patients post-PCI.
INTRODUCTION: inhibitor is the current standard. However, DAPT is associated with an increased risk of bleeding. DAPT duration and intensity should be modulated according to the patient's specific risk profile to optimize outcomes. AREAS COVERED: inhibitor should be considered in patients at increased risk of bleeding. Platelet function and genetic testing may help guiding the decision making. Antiplatelet agents also have specific drug-related adverse effects that clinicians should be aware of. EXPERT OPINION: Management of ACS patients has largely shifted over time, in order to achieve a patient-oriented approach. Development of specific scores based on genetic and clinical characteristics to predict patient's responsiveness to clopidogrel may allow to further reduce ischemic events, while technological and pharmacological advances are paving the way for further reduction of bleeding risk while preserving efficacy.
No takes yet. Share an insight, caveat, or question.
Laudani et al. (2025) conducted a review in Acute coronary syndrome undergoing percutaneous coronary intervention. Oral antiplatelet strategies (DAPT) was evaluated. Modulating dual antiplatelet therapy duration and intensity based on patient-specific risk profiles may optimize ischemic and bleeding outcomes in acute coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: